The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Orlistat, a New Lipase Inhibitor for the Management of Obesity
Open accessAbstract
Orlistat, a weight‐loss agent with a novel mechanism of action, recently was approved by the Food and Drug Administration for the treatment of obesity. It inhibits gastric and pancreatic lipases in the lumen of the gastrointestinal tract to decrease systemic absorption of dietary fat. In several trials lasting up to 2 years, orlistat was more effective than diet alone for weight reduction and maintenance of lost weight. Orlistat treatment also results in modest improvements in total cholesterol, low‐density lipoprotein, blood pressure, and fasting glucose and insulin concentrations. The major adverse effects are gastrointestinal, usually occur early in therapy, and tend to decrease with continued treatment. Because orlistat may decrease the absorption of fat‐soluble vitamins, a standard multiple‐vitamin supplement is recommended daily during therapy to prevent abnormalities in vitamin serum concentrations. The potential for severe gastrointestinal discomfort and the modest degree of weight loss may limit the agent's clinical utility. Its long‐term safety and effectiveness for weight maintenance, cost‐effectiveness of treatment, and overall reduction in obesity‐related morbidity and mortality remain to be determined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Actual causes of death in the United States
McGinnis, J. M. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510180077038 · Cited by 5,480
Overweight and obesity in the United States: prevalence and trends, 1960–1994
Flegal, K., Carroll, M., Kuczmarski, R., & Johnson, C. (1998) · International Journal of Obesity · doi:10.1038/sj.ijo.0800541 · Cited by 3,045
Pi-Sunyer, F. X. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-7_part_2-199310011-00006 · Cited by 1,371
Beneficial health effects of modest weight loss.
Dj, G. (1992) · PubMed · Cited by 1,263
Current Estimates of the Economic Cost of Obesity in the United States
Wolf, A. M., & Colditz, G. A. (1998) · Obesity Research · doi:10.1002/j.1550-8528.1998.tb00322.x · Cited by 1,244
Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947 · cited 6×
“5% of those receiving placebo.(26) Subjects in the second study included 688 patients (average BMI 36 kg/m(2), average weight 99 kg) seen at obesity treatment centers throughout Europe.”
BackgroundMethodInfluentialHollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Weiss, S. R., Crockett, S. E., Kaplan, R. A., Comstock, J., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1288 · Cited by 654
Rosenbaum, M., Leibel, R. L., & Hirsch, J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708073370606 · Cited by 584
Cited by
Yanovski, S. Z., & Yanovski, J. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmra012586 · Cited by 544
Self-citationRegulation of intestinal lipid metabolism: current concepts and relevance to disease
Ko, C.-W., Qu, J., Black, D. D., & Tso, P. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0250-7 · Cited by 510
Lipase Inhibitors for Obesity: A Review
Liu, T.-T., Liu, X.-T., Chen, Q.-X., & Shi, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110314 · Cited by 403
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 359
Corkey, B. E. (2012) · Diabetes · doi:10.2337/db11-1483 · Cited by 285
Metadata
- Authors
- Heck, A. M., Yanovski, J. A., & Calis, K. A.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2000-03
- Volume
- 20
- Issue
- 3
- Pages
- 270-279
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2030843949
- Cited by
- 572
- References
- 39
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Orlistat, a New Lipase Inhibitor for the Management of Obesity. https://app.cochat.ai/papers/10.1592/phco.20.4.270.34882
- The paper
- Heck, A. M., Yanovski, J. A., & Calis, K. A. (2000). Orlistat, a New Lipase Inhibitor for the Management of Obesity. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1592/phco.20.4.270.34882
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
